Document is current
Any future updates will be listed below
-
Authors
Han, Mookyoung https://orcid.org/0009-0004-8007-5711
Frieg, Benedikt https://orcid.org/0000-0002-7877-0262
Matthes, Dirk
Leonov, Andrei
Ryazanov, Sergey
Giller, Karin
Nimerovsky, Evgeny
Stampolaki, Marianna
Xue, Kai
Overkamp, Kerstin
Dienemann, Christian https://orcid.org/0000-0002-2172-5110
Riedel, Dietmar
Giese, Armin
Becker, Stefan https://orcid.org/0000-0003-2041-5740
de Groot, Bert L. https://orcid.org/0000-0003-3570-3534
Schröder, Gunnar F. https://orcid.org/0000-0003-1803-5431
Andreas, Loren B. https://orcid.org/0000-0003-3216-9065
Griesinger, Christian https://orcid.org/0000-0002-1266-4344
-
Funding
Funding for this research was provided by:
Max-Planck-Gesellschaft
Deutsche Forschungsgemeinschaft (EXC 2067/1-0390729940)
- License Information
-
More Information
Article History
Received: 28 May 2025
Accepted: 16 September 2025
First Online: 3 October 2025
Competing interests
: A. G. and C. G. are co-founders of MODAG. A.G. is a full-time employee of MODAG. A. L. and S.R. are partly employed by MODAG and are beneficiaries of the phantom share program of MODAG GmbH. A.L., S.R., C.G., and A.G. are co-inventors of WO/2010/000372. Anle138b is licensed by Teva Pharmaceutical Industries Ltd and is in clinical development in collaboration with MODAG. B.F. is an AstraZeneca employee. The remaining authors declare no competing interests.
